- Home
- FRME vs OLMA Comparison
FRME vs OLMA Comparison
Compare FRME & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FRME | OLMA |
|---|---|---|
| Founded | 1893 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.6B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | FRME | OLMA |
|---|---|---|
| Price | $37.34 | $25.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $47.33 | $40.50 |
| AVG Volume (30 Days) | 286.7K | ★ 2.6M |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | ★ 32.99 | N/A |
| EPS | ★ 4.00 | N/A |
| Revenue | ★ $649,589,000.00 | N/A |
| Revenue This Year | $13.81 | N/A |
| Revenue Next Year | $14.43 | N/A |
| P/E Ratio | $9.36 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $33.13 | $2.86 |
| 52 Week High | $45.62 | $36.26 |
Technical Indicators
Market Signals| Indicator | FRME | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 44.88 | 48.35 |
| Support Level | $38.06 | $25.85 |
| Resistance Level | $38.96 | $36.26 |
| Average True Range (ATR) | 0.59 | 2.22 |
| MACD | -0.20 | -1.29 |
| Stochastic Oscillator | 21.36 | 7.62 |
Price Performance
Historical ComparisonAbout FRME First Merchants Corporation
First Merchants Corp, through its subsidiaries, provides its customers with financial services delivered locally by bankers. It offers personal banking, business banking, real estate mortgage lending, cash management services, brokerage, wealth management, and insurance. The company reports in only one segment which is community banking.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.